Melissa Maguire
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Melissa Maguire has a total of 89 co-authors. Here are the top co-authors by number of shared publications:
- Andrew J. Larner
Department of Translational Neuroscience & Stroke, Institute of Neurology, University College London, London, UK
3 shared publications - Paul Chumas
Department of Neurosurgery Leeds Teaching Hospitals Leeds UK
3 shared publications - Charlotte Lawthom
Aneurin Bevan University Health Board, Newport NP11 5GH, UK
2 shared publications - John Goodden
The Leeds Children’s Hospital, Department of Paediatric Neurosurgery, Leeds General Infirmary, Leeds, UK
2 shared publications - John Paul Leach
Global Medical Department Angelini Pharma S.p.A Rome Italy
2 shared publications - Matthew Tanti
Faculty of Medicine and Health, University of Leeds, Leeds, UK
2 shared publications
Latest Publications
- 16 June 2026
- Published by Springer Nature in Journal of Neurology
- Vol. 273 (7) , 401
Helen Gertrude Leyton (1874–1959)
- 16 June 2026
- Published by Springer Nature in Journal of Neurology
- Vol. 273 (7) , 401
Helen Gertrude Leyton (1874–1959)
- Open Access
- 17 April 2026
- Published by Taylor & Francis in Journal of the History of the Neurosciences
- Vol. 35 (3) , 290-306
Women and the Neurological Society, 1897–1907
The Neurological Society of London, later the Neurological Society of the United Kingdom, was the first society dedicated to the discipline of neurology to be founded in the United Kingdom. During its period of existence, 1885/1886 to 1907, membership was exclusively male. However, examination of the Society's extant records shows that four women scientists and doctors had interactions with the society: Laura Forster, Rachel Alcock, Mary Darby Sturge, and Helen Stewart. These interactions, examined here, show evidence of the obstructions professional women faced when attempting to enter the male enclave of medical societies, despite the notional inclusivity of the Society's rules and enlightened attitudes evinced by some Society members.
- 17 April 2026
- Published by Taylor & Francis in Journal of the History of the Neurosciences
- Vol. 35 (3) , 290-306
Open AccessWomen and the Neurological Society, 1897–1907
The Neurological Society of London, later the Neurological Society of the United Kingdom, was the first society dedicated to the discipline of neurology to be founded in the United Kingdom. During its period of existence, 1885/1886 to 1907, membership was exclusively male. However, examination of the Society's extant records shows that four women scientists and doctors had interactions with the society: Laura Forster, Rachel Alcock, Mary Darby Sturge, and Helen Stewart. These interactions, examined here, show evidence of the obstructions professional women faced when attempting to enter the male enclave of medical societies, despite the notional inclusivity of the Society's rules and enlightened attitudes evinced by some Society members.
- 8 December 2025
- Published by Springer Nature in Journal of Neurology
- Vol. 273 (1) , 15
Laura Forster (1858–1917)
- 8 December 2025
- Published by Springer Nature in Journal of Neurology
- Vol. 273 (1) , 15
Laura Forster (1858–1917)
- Open Access
- 26 June 2024
- Published by Elsevier in Epilepsy & Behavior
- Vol. 158, 109906
Efficacy and tolerability of Brivaracetam in people with intellectual disability compared to those without intellectual disability
- 26 June 2024
- Published by Elsevier in Epilepsy & Behavior
- Vol. 158, 109906
Open AccessEfficacy and tolerability of Brivaracetam in people with intellectual disability compared to those without intellectual disability
- Open Access
Motor seizures confer overall survival benefit in who grade 2 glioma
Objective: The prevalence of epilepsy in World Health Organization (WHO) grade 2 glioma is high, with seizures being the presenting symptom in 60%–90%. We explore the epidemiology of seizures in this patient population in a regional neurosurgical center. Methods: Electronic health records of patients with histologically‐proven WHO grade 2 glioma ( n = 228) were reviewed between 1997 and 2021, with data collected including patient demographics, epilepsy prevalence, and seizure semiology. The influence of seizure type on overall survival was calculated using a Cox proportional hazards model. Results: Overall, 197 of 228 patients (86.4%) were diagnosed with epilepsy—either at presentation or during the course of their disease. Male patients were more likely than female patients to be diagnosed with epilepsy (91.1% vs 77.1%, p = .003) and, in those with epilepsy, more likely to experience at least one focal to bilateral tonic–clonic seizure (69.4% vs 54.1%, p = .05). Patients with left‐sided tumors were twice as likely to have experienced a focal to bilateral tonic–clonic seizure ( p = .02, odds ratio [OR] = .47). Predominantly experiencing seizures with motor activity appeared to confer better overall survival, with a 65% decrease in the risk of death 10 years post diagnosis (hazard ratio [HR] = .35, p = .02). This is despite accounting for previously described prognostic markers including tumor histology/genetics, time from diagnosis to surgery, and the extent of tumor resection. Significance: Motor seizure activity is a frequent feature in WHO grade 2 glioma and appears to confer a survival benefit regardless of histology or surgical factors. Seizures due to dominant hemisphere tumors may be more likely to propagate and cause bilateral tonic–clonic activity.
Open AccessMotor seizures confer overall survival benefit in who grade 2 glioma
Objective: The prevalence of epilepsy in World Health Organization (WHO) grade 2 glioma is high, with seizures being the presenting symptom in 60%–90%. We explore the epidemiology of seizures in this patient population in a regional neurosurgical center. Methods: Electronic health records of patients with histologically‐proven WHO grade 2 glioma ( n = 228) were reviewed between 1997 and 2021, with data collected including patient demographics, epilepsy prevalence, and seizure semiology. The influence of seizure type on overall survival was calculated using a Cox proportional hazards model. Results: Overall, 197 of 228 patients (86.4%) were diagnosed with epilepsy—either at presentation or during the course of their disease. Male patients were more likely than female patients to be diagnosed with epilepsy (91.1% vs 77.1%, p = .003) and, in those with epilepsy, more likely to experience at least one focal to bilateral tonic–clonic seizure (69.4% vs 54.1%, p = .05). Patients with left‐sided tumors were twice as likely to have experienced a focal to bilateral tonic–clonic seizure ( p = .02, odds ratio [OR] = .47). Predominantly experiencing seizures with motor activity appeared to confer better overall survival, with a 65% decrease in the risk of death 10 years post diagnosis (hazard ratio [HR] = .35, p = .02). This is despite accounting for previously described prognostic markers including tumor histology/genetics, time from diagnosis to surgery, and the extent of tumor resection. Significance: Motor seizure activity is a frequent feature in WHO grade 2 glioma and appears to confer a survival benefit regardless of histology or surgical factors. Seizures due to dominant hemisphere tumors may be more likely to propagate and cause bilateral tonic–clonic activity.
- 24 July 2023
- Published by International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)
Oedema as a prognostic factor for seizures in meningioma - a systematic review and meta-analysis
INPLASY202370101 Oedema as a prognostic factor for seizures in meningioma – a systematic review and meta-analysis Keywords: meningioma; seizures; epilepsy; oedema; edema; prognostic factors; …
- 24 July 2023
- Published by International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)
Oedema as a prognostic factor for seizures in meningioma - a systematic review and meta-analysis
INPLASY202370101 Oedema as a prognostic factor for seizures in meningioma – a systematic review and meta-analysis Keywords: meningioma; seizures; epilepsy; oedema; edema; prognostic factors; …
- 25 January 2023
- Published by BMJ in Practical Neurology
- Vol. 23 (3) , 251-252
Adult-onset leukoencephalopathy with calcifications and cysts
- 25 January 2023
- Published by BMJ in Practical Neurology
- Vol. 23 (3) , 251-252
Adult-onset leukoencephalopathy with calcifications and cysts
- Open Access
Levetiracetam as a first‐line antiseizure medication in WHO grade 2 glioma: Time to seizure freedom and rates of treatment failure
Objective: The high seizure burden seen in World Health Association (WHO) grade 2 gliomas is well documented. This study aims to identify factors that influence the probability of seizure freedom (12 months of seizure remission) and treatment failure (antiseizure medication [ASM] cessation or introduction of an alternative) in patients with WHO grade 2 glioma.Methods: This is a retrospective observational analysis of patients from a regional UK neurosurgical center with histologically proven (n = 146) WHO grade 2 glioma and brain tumor related epilepsy. Statistical analyses using both Kaplan‐Meier and Cox proportional hazards models were undertaken, with a particular focus on treatment outcomes when the commonly prescribed ASM levetiracetam (n = 101) is used as first line.Results: Treatment with levetiracetam as a first‐line ASM resulted in a significant increase in the probability of seizure freedom (p < .05) at 2 years compared with treatment with an alternative ASM. Individuals presenting with focal seizures without bilateral tonic‐clonic progression were between 39% and 42% significantly less likely to reach seizure freedom within 10 years (p < .05) and 132% more likely to fail treatment by 5 years (p < .01) when compared to individuals who had seizures with progression to bilateral tonic‐clonic activity. ASM choice did not significantly affect treatment failure rates.Significance: More than two‐thirds of patients with WHO grade 2 glioma related epilepsy treated with levetiracetam first line achieve seizure freedom within 2 years and it is a reasonable first‐choice agent. Experiencing mainly focal seizures without progression infers a significant long‐term reduction in the chance of seizure freedom. Further studies are needed to inform ASM selection.
Open AccessLevetiracetam as a first‐line antiseizure medication in WHO grade 2 glioma: Time to seizure freedom and rates of treatment failure
Objective: The high seizure burden seen in World Health Association (WHO) grade 2 gliomas is well documented. This study aims to identify factors that influence the probability of seizure freedom (12 months of seizure remission) and treatment failure (antiseizure medication [ASM] cessation or introduction of an alternative) in patients with WHO grade 2 glioma.Methods: This is a retrospective observational analysis of patients from a regional UK neurosurgical center with histologically proven (n = 146) WHO grade 2 glioma and brain tumor related epilepsy. Statistical analyses using both Kaplan‐Meier and Cox proportional hazards models were undertaken, with a particular focus on treatment outcomes when the commonly prescribed ASM levetiracetam (n = 101) is used as first line.Results: Treatment with levetiracetam as a first‐line ASM resulted in a significant increase in the probability of seizure freedom (p < .05) at 2 years compared with treatment with an alternative ASM. Individuals presenting with focal seizures without bilateral tonic‐clonic progression were between 39% and 42% significantly less likely to reach seizure freedom within 10 years (p < .05) and 132% more likely to fail treatment by 5 years (p < .01) when compared to individuals who had seizures with progression to bilateral tonic‐clonic activity. ASM choice did not significantly affect treatment failure rates.Significance: More than two‐thirds of patients with WHO grade 2 glioma related epilepsy treated with levetiracetam first line achieve seizure freedom within 2 years and it is a reasonable first‐choice agent. Experiencing mainly focal seizures without progression infers a significant long‐term reduction in the chance of seizure freedom. Further studies are needed to inform ASM selection.
- Open Access
- 17 November 2022
- Published by Springer Nature in Trials
- Vol. 23 (1) , 1-8
Protocol for the development of an international Core Outcome Set for treatment trials in adults with epilepsy: the EPilepsy outcome Set for Effectiveness Trials Project (EPSET)
Background: A Core Outcome Set (COS) is a standardised list of outcomes that should be reported as a minimum in all clinical trials. In epilepsy, the choice of outcomes varies widely among existing studies, particularly in clinical trials. This diminishes opportunities for informed decision-making, contributes to research waste and is a barrier to integrating findings in systematic reviews and meta-analyses. Furthermore, the outcomes currently being measured may not reflect what is important to people with epilepsy. Therefore, we aim to develop a COS specific to clinical effectiveness research for adults with epilepsy using Delphi consensus methodology. Methods: The EPSET Study will comprise of three phases and follow the core methodological principles as outlined by the Core Outcome Measures in Effectiveness Trials (COMET) Initiative. Phase 1 will include two focused literature reviews to identify candidate outcomes from the qualitative literature and current outcome measurement practice in phase III and phase IV clinical trials. Phase 2 aims to achieve international consensus to define which outcomes should be measured as a minimum in future trials, using a Delphi process including an online consensus meeting involving key stakeholders. Phase 3 will involve dissemination of the ratified COS to facilitate uptake in future trials and the planning of further research to identify the most appropriate measurement instruments to use to capture the COS in research practice. Discussion: Harmonising outcome measurement across future clinical trials should ensure that the outcomes measured are relevant to patients and health services, and allow for more meaningful results to be obtained. Core Outcome Set registration: COMET Initiative as study 118.
- 17 November 2022
- Published by Springer Nature in Trials
- Vol. 23 (1) , 1-8
Open AccessProtocol for the development of an international Core Outcome Set for treatment trials in adults with epilepsy: the EPilepsy outcome Set for Effectiveness Trials Project (EPSET)
Background: A Core Outcome Set (COS) is a standardised list of outcomes that should be reported as a minimum in all clinical trials. In epilepsy, the choice of outcomes varies widely among existing studies, particularly in clinical trials. This diminishes opportunities for informed decision-making, contributes to research waste and is a barrier to integrating findings in systematic reviews and meta-analyses. Furthermore, the outcomes currently being measured may not reflect what is important to people with epilepsy. Therefore, we aim to develop a COS specific to clinical effectiveness research for adults with epilepsy using Delphi consensus methodology. Methods: The EPSET Study will comprise of three phases and follow the core methodological principles as outlined by the Core Outcome Measures in Effectiveness Trials (COMET) Initiative. Phase 1 will include two focused literature reviews to identify candidate outcomes from the qualitative literature and current outcome measurement practice in phase III and phase IV clinical trials. Phase 2 aims to achieve international consensus to define which outcomes should be measured as a minimum in future trials, using a Delphi process including an online consensus meeting involving key stakeholders. Phase 3 will involve dissemination of the ratified COS to facilitate uptake in future trials and the planning of further research to identify the most appropriate measurement instruments to use to capture the COS in research practice. Discussion: Harmonising outcome measurement across future clinical trials should ensure that the outcomes measured are relevant to patients and health services, and allow for more meaningful results to be obtained. Core Outcome Set registration: COMET Initiative as study 118.
- 24 September 2022
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 102, 22-31
Wired for sound: The effect of sound on the epileptic brain
- 24 September 2022
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 102, 22-31
Wired for sound: The effect of sound on the epileptic brain